MedPath

A study to evaluate the Efficacy of E-IN-05 in subjects of Primary Insomnia

Phase 1
Conditions
Health Condition 1: null- Primary Insomnia
Registration Number
CTRI/2011/11/002130
Lead Sponsor
Enovate Biolife Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other (Terminated)
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Case of primary Insomnia as diagnosed by the investigator

- Sleep disorder indicated by one or more of the following:

- History of sleep duration of less than 4.5 hrs/ night

- History of sleep latency of >= 60 min

- History of tiredness post awakening

- History of presence of above symptoms for >= 6 months.

- Able and willing to follow all study related instructions and to make all required visits

Exclusion Criteria

- Subjects not willing to discontinue insomnia medication

- Secondary forms of insomnia

- Concurrent history/ treatment of acute psychiatric illness (such as schizophrenia, acute panic attack, major depressive disorder etc.).

- Subjects with history of a substance use disorder

- History of uncontrolled diabetes, hypertension and other metabolic disorder.

- Clinical history of allergy/ hypersensitivity to one or more products of herbal origin.

- Pregnant / lactating women and women who are planning to get pregnant

- Recent (within last 3 months) participation in a clinical trial

- Recent (within last 15 days) use of any, herbal or homeopathic product for the insomnia.

- A medical condition, which in the Investigatorâ??s opinion may pose a threat to patient compliance e.g. case of seizures.

- Subjects otherwise judged by the investigator or sub -investigator to be inappropriate for inclusion in the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
â?¢Increase in sleep duration by 1-2 hrs/ day as assessed by patientâ??s sleep dairyTimepoint: â?¢Increase in sleep duration by 1-2 hrs/ day as assessed by patientâ??s sleep dairy
Secondary Outcome Measures
NameTimeMethod
1) Decrease in sleep latency <br/ ><br>2) Modified Pittsburgh Sleep Quality Index <br/ ><br>Timepoint: 1) Day 0, Day 21 and Day 42 <br/ ><br>2) Day 0, Day 21 and Day 42
© Copyright 2025. All Rights Reserved by MedPath